(Q37917774)

25 August 2017

1 reference

title

New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response (English)

1 reference

25 August 2017

1 reference

Erika Hamilton

1

1 reference

25 August 2017

Timothy M Clay

series ordinal

2

1 reference

25 August 2017

Kimberly L Blackwell

series ordinal

3

1 reference

25 August 2017

publication date

15 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

29

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

533-541

1 reference

The plasticity of gamma delta T cells: innate immunity, antigen presentation and new immunotherapy

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Perspectives of gammadelta T cells in tumor immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Bisphosphonates induce breast cancer cell death in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Bisphosphonates induce apoptosis in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Differential effects of bisphosphonates on breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Zoledronate Stimulates γδ T Cells in Prostate Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Activation of γδ T cells by bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Tumor-infiltrating T lymphocytes: friends or foes?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Human gamma delta T cells and tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Targeting the mevalonate pathway for improved anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Bisphosphonates: preclinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Management of the adverse effects associated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

RANKL inhibition for the management of patients with benign metabolic bone disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Influence of RANKL inhibition on immune system in the treatment of bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

Is cancer a disease of self-seeding?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2011.605413

10.3109/07357907.2011.605413

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference